Clinical Trial Update: CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab [Phase 4]

View source ↗

Summary

This clinical trial was withdrawn; it investigated switching from aflibercept (Eylea) to ranibizumab (Lucentis) for wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Wet Age-related Macular Degeneration (Wet AMD) | Phase 4 | Status: WITHDRAWN